|
Re: Sent to Sarah,
|
1
|
Resverlogix Corp.
|
Jun 12, 2022 01:30PM
|
|
Re: Sell Zenith Shares
|
1
|
Zenith Epigenetics
|
May 10, 2019 01:24AM
|
|
Re: Scientists warn of new coronavirus variant spreading across Europe.
|
3
|
Resverlogix Corp.
|
Nov 04, 2020 06:36PM
|
|
Re: RVXs up or down draft from ZENE???
|
3
|
Resverlogix Corp.
|
Jan 09, 2024 08:19PM
|
|
Re: Rumors starting again
|
1
|
Zenith Epigenetics
|
Nov 10, 2020 07:51AM
|
|
Re: Round one
|
6
|
Resverlogix Corp.
|
Jan 28, 2022 06:28AM
|
|
Re: Round one
|
2
|
Resverlogix Corp.
|
Jan 28, 2022 07:37AM
|
|
Re: Risk vs Reward moving forward!
|
8
|
Resverlogix Corp.
|
Dec 18, 2021 10:41AM
|
|
Re: Review of ZCC history
|
2
|
Zenith Epigenetics
|
Aug 29, 2023 10:37AM
|
|
Re: Resverlogix warrants to be delisted June 21
|
1
|
Resverlogix Corp.
|
Jun 14, 2021 03:07PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
3
|
Resverlogix Corp.
|
Jun 22, 2020 06:21PM
|
|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
2
|
Resverlogix Corp.
|
Oct 04, 2023 01:49PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
5
|
Resverlogix Corp.
|
Dec 22, 2020 10:08AM
|
|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
5
|
Resverlogix Corp.
|
Aug 29, 2023 06:49PM
|
|
Re: Received a reply too...
|
1
|
Resverlogix Corp.
|
Sep 12, 2017 02:30PM
|
|
Re: Questrade
|
|
Zenith Epigenetics
|
Jan 07, 2024 06:30PM
|
|
Re: Questrade
|
1
|
Zenith Epigenetics
|
Jan 05, 2024 12:41PM
|
|
Re: Questrade
|
2
|
Zenith Epigenetics
|
Jan 05, 2024 11:25PM
|
|
Re: Questions/comments sent to IR/Chris for Don to review & answer …
|
2
|
Resverlogix Corp.
|
Jul 29, 2024 07:24PM
|
|
Re: Q1- March 31, 2022 on SEDAR
|
5
|
Resverlogix Corp.
|
May 22, 2022 08:45PM
|
